Back to results
US 2026/0297154 A1Published application
Multi-Agonist and Use Thereof
AssigneeThe United Bio-Technology (Hengqin) Co., Ltd.
InventorsLiang Huang, Chunlai Cao, Huixing Deng, Cui Zhou, Xiuyi He, Xiaoxiao Liu, Xin Xie
Life of this patent
Estimating the term…
Abstract
The present application relates to the pharmaceutical and biological fields, particularly relates to a polypeptide compound of general formula (I) with triple agonist activity on glucagon like peptide-1 receptor (GLP-1 R), glucose-dependent insulinotropic poypeptide receptor (GIP R), and glucagon receptor (GCG R), and use thereof in the treatment of metabolic syndrome.
Claims10
-25. (canceled)
A polypeptide compound that is:
- Y-Aib-QGT-αMeF-TSDYSI-αMeL-LDKK(AEEAc-AEEAc-γGlu-CO(CH2)18COOH)AQ-Aib-AFIEYLLETGPSSGAPP-Ac3c-S—NH2 (SEQ ID NO:
- 1), or a pharmaceutically acceptable salt thereof.
A polypeptide compound that is:
- Y-Aib-QGT-αMeF-TSDYSI-αMeL-LDKK(AEEAc-AEEAc-γGlu-CO(CH2)18COOH)AQ-Aib-AFIEYLLETHPSSGAPP-Ac3c-S—NH2 (SEQ ID NO:
- 2), or a pharmaceutically acceptable salt thereof.
A polypeptide compound that is:
- Y-Aib-QGT-αMeF-TSDYSI-αMeL-LDKK(AEEAc-AEEAc-γGlu-CO(CH2)18COOH)AQ-Aib-AFIEYLLESHPSSGAPP-Ac3c-S—NH2 (SEQ ID NO:
- 3), or a pharmaceutically acceptable salt thereof.
Dependencies are inferred from the claim text.